Nombre del producto:(25R,52S)-52-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-25-(tert-butoxycarbonyl)-2,2-dimethyl-4,23,28,37,46-pentaoxo-3,32,35,41,44-pentaoxa-24,29,38,47-tetraazatripentacontan-53-oic acid

IUPAC Name:(2S)-6-[2-(2-{2-[2-(2-{2-[(4R)-5-(tert-butoxy)-4-[20-(tert-butoxy)-20-oxoicosanamido]-5-oxopentanamido]ethoxy}ethoxy)acetamido]ethoxy}ethoxy)acetamido]-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)hexanoic acid

CAS:2460751-66-8
Fórmula molecular:C66H105N5O16
Pureza:99% HPLC
Número de catálogo:CM1075331
Peso molecular:1224.59

Unidad de embalaje Stock disponible Precio($) Cantidad
CM1075331-25g in stock ǠşǠŸ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :2460751-66-8
Fórmula molecular:C66H105N5O16
Punto de fusión:-
Código de sonrisas:CC(C)(C)OC(=O)CCCCCCCCCCCCCCCCCCC(=O)N[C@H](CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)NCCCC[C@H](NC(=O)OCC1C2=CC=CC=C2C2=C1C=CC=C2)C(O)=O)C(=O)OC(C)(C)C
Densidad:
Número de catálogo:CM1075331
Peso molecular:1224.59
Punto de ebullición:
Nº Mdl:
Almacenamiento:

Category Infos

Fatty Acid Modified Side Chains
Fatty acid-modified side chains are small molecule modifiers and are one of the important factors that change the pharmacokinetic behavior of insulin products. Peptide drugs have the problem of short half-life and easy degradation in clinical practice. Introducing fatty acid-modified side chains into peptide drugs can increase the hydrophobicity of the drug and increase the biological half-life, thereby reducing the dosage and frequency of medication.